EXITED OCCIDENTAL PETROLEUM (OXY)
May 24, 2011
Exited Occidental Petroleum (OXY) with profit at $98.95. This position is now closed.
Proven Track Record of Most Accurate Analysis
Proven Track Record
of Most Accurate Analysis
Exited Occidental Petroleum (OXY) with profit at $98.95. This position is now closed.
Tech Data (TECD) has plunged after reporting earnings. The earnings were not bad, however, the bullish gurus had pushed Tech Data much higher than it deserved to be. The same bullish gurus are now proclaiming that the fall is a buying opportunity around $48.00. Well, Tech Data has now broken down from the support at $48.00 and is now trading at $46.80. We disagree with the bulls. The Quantitative Screen of the ZYX Change Method shows the fair value of Tech Data to be $41.00. There is a strong probability of Tech
Subscribers to ZYX Short Sell Change Alert received the following entry in real time on May11,2011 on Zagg (ZAGG): As we expected, ZAGG reported great earnings last night. The effect of the smart cover from iPad 2 will be felt in the coming quarters and over a period of time this should be a great trade. Long term target zone is $2. to $3. Short term target zone is $5. to $6.20. This is a very long term position. Conservative investors may consider adding to the position between $10.90 and $12.00. Those not in the stock may
Subscribers to the ZYX Short Sell Change Alert took profits on Xenoport (XNPT) on May 5,2011 at $7.35. Following was the entry on the Real Time Feed: Most of our subscribers have already realized over 20% profit on XNPT over a very short time. After earnings report, the stock is now down to $7.35. Those still holding a partial position may consider taking profits right here and completely exiting the position. The risk of continuing to hold the position outweighs the potential reward. Those not in the position should not enter. Inadvertently, this signal on Xenoport
Subscribers to ZYX Short Sell Change Alert took partial profits on Acorda Therapeutics (ACOR)at $30.20 on Friday. We are holding partial position for the prices to hit our target zone. This target zone was provided to the subscribers of ZYX Short Sell Change Alert at the time of the trade entry on Acorda Therapeutics.
LinkedIn (LNKD) frenzy continues. Fundamentals do not justify buying LinkedIn at this level. LinkedIn is no Google (GOOG). Options will start trading Thursday and stock should become available for shorting after that. An analysis of the historical data of similar situations shows that shorting this stock in the near term will be a disaster. There are low risk ways to make money from LinkedIn. Here are the excerpts from my article on Seeking Alpha: LinkedIn: Overvalued, But a Dangerous Short LinkedIn (LNKD) went public Thursday, setting a frenzy on Wall Street. It was
We are taking partial profits on LTD right here at $39.22. We will leave the rest to hit our target zone.
Acorda Therapeutics (ACOR) is up due to the positive opinion on Marketing Authorization Application for its MS drug Ampyra in Europe. This approval for Acorda Therapeutics was expected. The big move in Acorda is unwarranted. We are short selling in the strength now with an average price $32.98 and will add if the stock goes higher. As a full disclosure, this alert was earlier published in ZYX Short Sell Change Alert — Real Time Feed. For stops and targets please see ZYX Short Sell Change Alert.